• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vigil Neuroscience, Inc. - Common Stock (NQ: VIGL )

    3.948 +0.088 (+2.28%)
    Streaming Delayed Price Updated: 10:23 AM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Vigil Neuroscience, Inc. - Common Stock

    < Previous 1 2 3 4 5 Next >
    Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Neuroscience to Present at Cantor Global Healthcare Conference
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Neuroscience: Q4 Earnings Insights
    Via Benzinga
    Vigil Neuroscience to Present at Upcoming September Investor Conferences
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q2 2024
    VIGL stock results show that Vigil Neuroscience beat analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Neuroscience Highlights Publication on ALSP Genetic Mutation Prevalence in Neurology Genetics
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Presents Data on its Small Molecule TREM2 Agonist Program at 2024 Alzheimer's Association International Conference (AAIC)
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's Candidate Shows Significant Impact On Disease Bimarker
    Vigil Neuroscience reports promising interim results from its Phase 1 trial of VG-3927, showing a strong safety, tolerability, and pharmacokinetic profile in healthy volunteers. The data support... 
    Via Benzinga
    Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Why Is Tonix Pharmaceuticals (TNXP) Stock Down 33% Today?
    Tonix Pharmaceuticals stock is falling on Thursday after the company announced a proposed public offering for shares of TNXP. 
    Via InvestorPlace
    Why Is Branchout Food (BOF) Stock Down 39% Today?
    Branchout Food stock is down on Thursday after the company priced an offering of 1.75 million shares of BOF at 80 cents each. 
    Via InvestorPlace
    Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?
    Vigil Neuroscience stock is up with heavy trading of VIGL shares this morning on news of a $40 million investment from Sanofi. 
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning! 
    Via InvestorPlace
    Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    3 Penny Stocks With the Power to 10X Your $1k Investment: June Edition
    Penny stocks are risky because of their insane volatility — but these have a chance to 10x your investments. 
    Via InvestorPlace
    3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
    Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year. 
    Via InvestorPlace
    Vigil Neuroscience to Present in Upcoming June Investor Conferences
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    VIGL Stock Earnings: Vigil Neuroscience Beats EPS for Q1 2024
    VIGL stock results show that Vigil Neuroscience beat analyst estimates for earnings per share the first quarter of 2024. 
    Via InvestorPlace
    Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    VIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023
    VIGL stock results show that Vigil Neuroscience missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
    From Vigil Neuroscience, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.